Does mycophenolate mofetil increase the incidence of infections in renal transplant recipients?

Drugs under Experimental and Clinical Research

Volumn 31, Issue 5-6, 2005, Pages 199-205

  Prokopenko, E ^a   Scherbakova, E ^a   Vatazin, A ^a   Pasov, S ^a   Budnikova, N ^a   Agafonova, S ^a  

^a M F VLADIMIRSKY MOSCOW REGIONAL RESEARCH CLINICAL INSTITUTE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; KETOCONAZOLE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE;

ADULT; ARTICLE; BACTERIAL INFECTION; CADAVER DONOR; CLINICAL ARTICLE; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTIOUS COMPLICATION; KIDNEY TRANSPLANTATION; MALE;

AZATHIOPRINE; BACTERIAL INFECTIONS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PREDNISOLONE; VIRUS DISEASES;

EID: 30144437520     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation, 61, 1029, 1996.
2. Wiesel M., Carl S. A placebo-controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group. J. Urol., 159, 28, 1998.
3. Bernabeu-Wittel M., Naranjo M., Cisneros J.M., et al. Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression. Eur. J. Clin. Microbiol. Infect. Dis., 21, 173, 2002.
4. Abbott K.C., Hypolite I.O., Viola R., et al. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Ann. Epidemiol., 12, 402, 2002.
5. De Maar E.F., Verschuuren E.A., Homan vd Heide J.J., et al. Effects of changing immunosuppressive regimen on the incidence, duration, and viral load of cytomegalovirus infection in renal transplantation: A single center report. Transplant. Infect. Dis., 4, 17, 2002.
6. Pérez-Valentín MA, Cofán F., Sole M., et al. Atypical cytomegalovirus in renal transplantation: A new form of presentation. Nefrologia, 22, 381, 2002.
7. Reichenberger F., Dickenmann M., Binet I., et al. Diagnostic yield of bronchoalveolar lavage following renal transplantation. Transplant. Infect. Dis., 3, 2, 2001.
8. Di Landro D., Sarzo G., Marchini F. New immunosuppressive treatment in kidney transplantation. Clin. Nephrol., 53, S23-32, 2000.
9. Sarmiento J.M., Munn S.R., Paya C.V., Velosa J.A., Nguyen J. H. Is cytomegalovirus infection related to mycophenolate mofetil after kidney transplantation? A case-control study. Clin. Transplant., 12, 371, 1998.
10. Moreso F., Seron D., Morales J.M., et al. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin. Transplant., 12, 198, 1998.
11. Giral M., Nguyen J.M., Daguin R, et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am. Soc. Nephrol., 12, 1758, 2001.
12. Kim YS., Moon J.I., Kim S.I., Park K. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. Transplantation, 68, 578, 1999.
13. Triemer H.L., Pearson TC., Odon K.L., Larsen C.P Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation. Clin. Transplant., 14 (4 Pt 2), 413, 2000.
14. Geetha D., Zachary J.B., Baldado H.M., Kronz J.D., Kraus E.S, Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: A case report and review of literature. Clin. Transplant., 14, 586, 2000.
15. Rostaing L., Izopet J., Sandres K., Cisterne J.M., Puel J., Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation, 69, 991, 2000.
16. Eberhard O.K., Kliem V., Brunkhorst R. Five cases of Kaposi's sarcoma in kidney graft recipients: possible influence of the immunosuppressive therapy. Transplantation, 67, 180, 1999.
17. Waiser J., Schotcshel R., Budde K., Neumayer H.H. Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation. Am. J. Kidney Dis., 35, 12, 2000.
18. Humar A. Ramcharan T, Denny R., Gillingham K.J., Payne W.D., Matas A.J. Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation, 72, 1920, 2001.
19. Maes B.D., Dalle I., Geboes K., et al Erosive enterocolitisin mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation, 75, 665, 2003.
20. Johnson D.W., Nicol D.L, Purdie D.M., et al. Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients? Transplantation, 73, 1158, 2002.
21. Meier-Kriesche H.U., Friedman G., Jacobs M., Mulgaonkar S., Vaghela M., Kaplan B, Infectious complications in geriatric renal transplant patients: Comparison of two immunosuppressive protocols. Transplantation, 68, 1496, 1999.